Health Condition 1: D509- Iron deficiency anemia, unspecified
Conditions
Interventions
Intervention1: Qurs Kushta Khabsul Hadeed(tablet) with Sharbat-e-Anar shirin(syrup)
: 1 tablet of Qurs Kushta Khabsul Hadeed(130mg) twice a day with 25ml of sharbat--e-Anar shirin twice a day for 2 mo
Sponsors
Ayurvedic and Unani Tibbia College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1.Clinically diagnosed patients with iron deficiency anaemia. 2.Patients between the age of 18 and 60 years of either sex. 3.Hemoglobin Level more than 7gm/dl and less than 12 gm/dl for females or 13gm/dl for males. 4.Patients suffering from microcytic hypochromic anaemia on peripheral smear. 5.Serum ferritin level less than 30ng/ml. 6.Patients able to understand and follow the protocol for the duration of the study. 7.Patients having blood urea, serum creatinine, SGOT, SGPT, within normal limit. 8.Patients willing to participate in the study and sign the informed consent form. 1.Clinically diagnosed patients with iron deficiency anaemia. 2.Patients between the age of 18 and 60 years of either sex. 3.Hemoglobin Level more than 7gm/dl and less than 12 gm/dl for females or 13gm/dl for males. 4.Patients suffering from microcytic hypochromic anaemia on peripheral smear. 5.Serum ferritin level less than 30ng/ml. 6.Patients able to understand and follow the protocol for the duration of the study. 7.Patients having blood urea, serum creatinine, SGOT, SGPT, within normal limit. 8.Patients willing to participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Pregnant and lactating women. 2.Patients suffering from diabetes mellitus/tuberculosis/cardiovascular diseases/liver diseases/kidney diseases or any other co-morbidities. 3.Patient already taking treatment for anaemia. 4.Patients suffering from other type of anemia like pernicious anemia,thallasemia or megaloblastic anemia. 5.Patients with bleeding history, e.g., Abnormal uterine bleeding, piles/rectal bleeding,haemoptysis and hematemesis etc. 6.Patients taking blood thinners or any other drug which causes haemolysis. 7.Patients not willing to sign the consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To assess the Safety and Efficacy of proposed compound unani formulation. a.Improvement in Subjective parameters of IDA. b.Improvement in objective parameters of IDA. 2.To compare the results of two Unani compound formulations in the management of Iron Deficiency Anemia in respect of safety and Efficacy. Timepoint: 1.To Evaluate efficacy. a.Assesement of subjective parameters at baseline,15th,30th,45th and 60th day. b.Assessment of objective parameters at baseline and after the 60th day. 2.To evaluate safety. Haemogram, LFT, KFT at baseline and after 60th day | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Improvement in quality of life.Timepoint: Assessment of QoL at baseline & after 60th day. | — |
Countries
India
Contacts
Public ContactKHAN SAIMA PARVEEN
Ayurvedic and Unani Tibbia College and Hospital
Outcome results
None listed